New to site?


Login

Lost password? (X)

Already have an account?


Signup

(X)
Farooq

Boehringer Ingelheim advances first pan-KRAS inhibitor BI 1701963 into clinical testing

HomeINDUSTRY NEWSBoehringer Ingelheim advances first pan-KRAS inhibitor BI 1701963 into clinical testing
31
Oct
Boehringer Ingelheim advances first pan-KRAS inhibitor BI 1701963 into clinical testing

Boehringer IngelheimBoehringer Ingelheim presented promising preclinical data from its pan-KRAS program including the novel, oral inhibitor BI 1701963 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, USA(1). Based on these results the compound has been advanced to Phase I clinical testing alone and in combination with trametinib in patients with different types of advanced solid tumors with KRAS mutations.Original Article

Tags:

    Related Posts
    Leave A Comment

    Leave A Comment